NCT04179110 2022-02-22
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
Yale University
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT01282463 2019-09-09
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT00515697 2014-06-18
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Phase 2 Completed